This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Annji Pharmaceutical Co., Ltd.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Innovations of Chan-Hui Huang in Cancer Treatment
Introduction
Chan-Hui Huang is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative work on histone deacetylases (HDACs) inhibitors. His research focuses on developing compounds that can effectively target various cancer cell lines.
Latest Patents
Chan-Hui Huang holds 1 patent related to his work on HDACs inhibitors. The patent discloses a structural formula for these inhibitors, which includes a benzene ring and a cyclohexane ring, both of which can be substituted. The HDACs inhibitors developed by Huang demonstrate cytotoxicity against a range of cancer types, including glioma, breast cancer, colon cancer, and several others. This innovation holds promise for treating tumors associated with the deregulation of histone deacetylases.
Career Highlights
Huang is currently associated with Annji Pharmaceutical Co., Ltd., where he continues to advance his research in cancer therapeutics. His work has the potential to impact the lives of many patients suffering from various forms of cancer.
Collaborations
Chan-Hui Huang collaborates with esteemed colleagues such as Ji-Wang Chern and Chao-Wu Yu. Their combined expertise enhances the research and development of effective cancer treatments.
Conclusion
Chan-Hui Huang's innovative work on HDACs inhibitors represents a significant advancement in cancer treatment. His contributions to the field are vital for developing new therapeutic options for patients in need.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile